Ex Vivo Generation of Human Anti–Pre-B Leukemia-Specific Autologous Cytolytic T Cells
Angelo A. Cardoso(Centro Infantil Boldrini), Lee M. Nadler(Dana-Farber Cancer Institute), John G. Gribben(Queen Mary University of London), Gordon J. Freeman(Dana-Farber Cancer Institute), Hernani M. Afonso(Dana-Farber Brigham Cancer Center), Stephen E. Sallan, Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Paolo Ghia(Vita-Salute San Raffaele University), Mark J. Seamon(University of Pennsylvania)
Cited by 128
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k